Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
04/2003
04/23/2003EP1304101A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
04/23/2003EP1303619A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction
04/23/2003EP1303596A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
04/23/2003EP1303538A2 Ghrelin antagonists
04/23/2003EP1303537A2 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases
04/23/2003EP1303533A2 Chimeric peptide immunogens, their preparation and use
04/23/2003EP1303308A2 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
04/23/2003EP1303273A1 New pharmaceutical composition and the process for its preparation
04/23/2003EP1303270A1 Method for treating cryptorchidism
04/23/2003EP1242445B1 14,15-cyclopropanosteroids of the 19-norandrostane series, method for producing said compounds and pharmaceutical preparation containing said compounds
04/23/2003EP1102739B1 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
04/23/2003CN1413230A Highly-neutralized ethylene copolymers and their use in golf balls
04/23/2003CN1413207A 5-membered ring heterocyclic compounds with nitrogen
04/23/2003CN1413118A Liquid composition of biodegradable block copolymer for drug delivery system and process for preparation thereof
04/23/2003CN1413117A Drugs, drinks or foods
04/23/2003CN1413107A Use of hypoglycemic agent for treating impaired clucose metabolism
04/23/2003CN1413105A Novel method of treatment
04/23/2003CN1411848A Chinese medicine liquor for clearing and activating channels and collaterals
04/23/2003CN1411809A Usage and composition of pyridine onium derivative for curing application
04/23/2003CN1411800A Cosmetic composition and method
04/23/2003CN1106384C Indoline-2-one derivatives, its preparing method and its medicinal compositions
04/23/2003CN1106383C Estrogenic agents
04/23/2003CN1106195C Use of thazolinedione derivatives and related antihyperglycemic agents in treatment of disease states at risk for progressing to non-insulin-dependent diabetes mellitus
04/22/2003US6552069 3-methyl-chroman and -thiochroman derivatives
04/22/2003US6552068 Having anti-estrogenic activity; for use in therapy
04/22/2003US6552010 Treatment of SLE with dehydroepiandrosterone
04/22/2003US6551996 Super-active porcine growth hormone releasing hormone analog
04/22/2003US6551626 Composition containing pyrrolizidine-alkaloid-free petasites
04/17/2003WO2003031939A2 Protein modification and maintenance molecules
04/17/2003WO2003031568A2 Intracellular signaling molecules
04/17/2003WO2003031472A2 Insulin mimetic amino acid sequences
04/17/2003WO2003031468A1 Therapeutic and diagnostic molecules that are capable of interacting with socs proteins
04/17/2003WO2003031464A2 Remodeling and glycoconjugation of peptides
04/17/2003WO2003031432A1 Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
04/17/2003WO2003031400A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3
04/17/2003WO2003031397A1 Acylsulfonamides as inhibitors of steroid sulfatase
04/17/2003WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003WO2003030930A1 Human 3 relaxin
04/17/2003WO2003030903A1 The use of tizanidine for treating metabolic disorders related to abnormal insulin secretion
04/17/2003WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003WO2003030833A2 Angiopoietin-2 specific binding agents
04/17/2003WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor
04/17/2003WO2003011293A3 Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
04/17/2003WO2002098852A3 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
04/17/2003WO2002083727A3 Nucleic acid sequences of hyperplasies and tumors of the thyroid
04/17/2003WO2002070706A3 Interleukin-8 homologous polypeptides and therapeutic uses thereof
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002017881A3 Transdermal pharmaceutical delivery composition
04/17/2003WO2001076573A3 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
04/17/2003WO2000037430A3 Use of androgen receptor suppressors
04/17/2003WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands
04/17/2003US20030073849 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
04/17/2003US20030073712 Antiinflamamtory agents; antiischemic agents
04/17/2003US20030073693 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
04/17/2003US20030073675 Novel 19-norsteroids substituted in position 11beta, preparation process and intermediates, application as medicines and pharmaceutical compositions containing them
04/17/2003US20030073673 Hormonal contraceptive product
04/17/2003US20030073630 Long lasting growth hormone releasing factor derivatives
04/17/2003US20030073609 Enhanced pharmacokinetic profile of intradermally delivered substances
04/17/2003US20030073167 DNA encoding SNORF36 receptors
04/17/2003US20030072797 Pharmaceutical compositions for oral administration
04/17/2003CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003CA2462892A1 Human 3 relaxin
04/17/2003CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003CA2461435A1 Angiopoietin-2 specific binding agents
04/17/2003CA2460476A1 Protein modification and maintenance molecules
04/17/2003CA2458645A1 Intracellular signaling molecules
04/17/2003CA2458453A1 Acylsulfonamides as inhibitors of steroid sulfatase
04/16/2003EP1302460A1 Indolecarboxylic compounds and their use as pharmaceutical compounds
04/16/2003EP1302201A1 Pharmaceutical composition improved in peroral absorbability
04/16/2003EP1301598A2 Cell cycle proteins and mitosis-associated molecules
04/16/2003EP1301595A2 G-protein coupled receptors
04/16/2003EP1301535A2 G-protein coupled receptors
04/16/2003EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies
04/16/2003EP1301522A1 Novel compounds and methods
04/16/2003EP1301516A1 Modulators of protein tyrosine phosphatases (ptpases)
04/16/2003EP1301514A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use
04/16/2003EP1301490A2 5-substituted 2-aryl-4-pyrimidinones
04/16/2003EP1301200A2 Peptide pharmaceutical formulations
04/16/2003EP1301184A2 Valproic acid and derivatives thereof as histone deacetylase inhibitors
04/16/2003EP1301173A1 A medicinal aerosol formulation
04/16/2003EP1121100B1 Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin
04/16/2003EP1090027B1 Novel 17-halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same
04/16/2003EP0972769B1 Novel amide derivatives and medicinal compositions thereof
04/16/2003EP0918455B1 Use of galanin to repair nerve damage
04/16/2003EP0912185B1 Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
04/16/2003CN1411440A Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
04/16/2003CN1411369A Biodegradable microparticles with novel erythropoietin stimulating protein
04/16/2003CN1410059A Treating method and medicine kit containing somatotrophic hormone secretory agent
04/16/2003CN1105576C Insulin analog formulation
04/15/2003US6548514 Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders
04/15/2003US6548494 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases
04/15/2003CA2084775C Method of treating human prostatic adenocarcinoma
04/10/2003WO2003029465A1 HepNaDC GENE
04/10/2003WO2003029445A1 Process for the production of cells exhibiting an islet-beta-cell-like state
04/10/2003WO2003029437A2 Secreted proteins
04/10/2003WO2003029410A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER
04/10/2003WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use
04/10/2003WO2003029268A1 Androstane 17-beta-carboxamides as androgen receptor modulators
04/10/2003WO2003029200A2 Compounds useful as reversible inhibitors of cysteine proteases
1 ... 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 ... 290